Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes

Diabetes Care 2018;41:662–663 | https://doi.org/10.2337/dc17-0053

Ian H. de Boer1 and George L. Bakris2

Diabetes, regardless of type, has well-accepted vascular consequences. In fact, atherosclerotic cardiovascular disease (CVD) is the most important cause of death attributable to diabetes (1). Acute complications of diabetes such as hypoglycemia, hyperglycemia, and diabetic ketoacidosis are important causes of morbidity and mortality beginning early in its course. However, microvascular and macrovascular complications drive excess mortality over the long term (2–4).

Diabetic kidney disease (DKD) is strongly associated with CVD (5). DKD may be a marker of cumulative vascular damage due to diabetes or may causally promote CVD through several mechanisms, such as blood pressure dysregulation, retention of uremic toxins, anemia, and altered mineral metabolism. Provocative studies suggest that the preponderance of excess CVD risk in both types 1 and 2 diabetes is restricted to people with DKD (6–8).

The question posed by Groop et al. (9) in this issue of Diabetes Care was whether patients with type 1 diabetes have heightened CVD mortality risk in the absence of DKD compared with people without diabetes. To examine this question, they looked at two different databases. The first was a registry of 10,737 Finnish children followed for 10 years after the initial diagnosis of type 1 diabetes, a period considered generally too early for DKD development. The mortality rate of children in the Finnish registry was compared with that of the general population as a standardized mortality ratio (SMR) that adjusts for demographic characteristics. Children with diabetes had a mortality rate of 8 per 10,000 person-years, yielding an SMR of 2.6. (An SMR of 1 would represent no difference.) The main cause of death was acute complications of diabetes.

A second cohort studied included 2,544 participants with type 1 diabetes from the Finnish Diabetic Nephropathy Study (FinnDiane) who were observed to have persistently normal urine albumin excretion (10). For each FinnDiane patient, mortality outcomes were compared with 1) the age- and sex-matched general population (as the SMR) or 2) three control individuals without diabetes selected from the Population Register Centre, matched for sex, age, and place of residence in the year of diabetes diagnosis in the FinnDiane patient.

In the FinnDiane cohort without albuminuria, the median age at baseline was 36 years, the median duration of diabetes was 16 years, and the mortality rate was 34 per 10,000 person-years. This mortality rate was not significantly different from the general Finnish population (SMR 1.02, 95% CI 0.84–1.22) but was modestly higher than in matched control subjects without diabetes (hazard ratio 1.33, 95% CI 1.06–1.66). The most frequent cause of death in the FinnDiane cohort was ischemic heart disease.

The authors reasonably concluded that compared with people without diabetes of similar age and sex, mortality rates are higher among people with type 1 diabetes even when DKD is not present. They further concluded that acute complications of type 1 diabetes drive excess mortality during the first 10 years while CVD is the main cause of mortality in later years.

This study is consistent with prior observations that DKD is a major driver of mortality in type 1 diabetes. Indeed, the mortality rate among FinnDiane participants without albuminuria (34 per 10,000 person-years) is substantially less than that previously reported for the overall FinnDiane cohort (7). In the Pittsburgh Epidemiology of Diabetes Complications Study of type 1 diabetes, mortality rates (per 10,000 person-years) were 30 for participants without albuminuria (similar to the current results from the comparable FinnDiane subset), 160 for those with microalbuminuria, 300 for those with macroalbuminuria, and 860 for those with end-stage renal disease (6).

Nonetheless, the observations published in the current study offer relevant guidance for clinical care of patients without DKD, suggesting continued vigilance to reduce CVD risk in addition to prevention of acute complications of diabetes. Within FinnDiane, smoking was more
common among those who died during follow-up (30.4% vs. 22.8%, high proportions that could be reduced to improve outcomes). Also, while there was almost a threefold higher number of people taking statins in the deceased group compared with those still alive at the end of follow-up, only 19% in the deceased group and 6.7% in the alive group were receiving statins at baseline. These proportions are far below the more than 65–70% of people receiving statins in contemporary trials among patients with type 2 diabetes (11,12). Moreover, the LDL cholesterol concentrations seen in both groups were far above the current guideline recommendations independent of statin use (11). In addition, although mean study blood pressures were reasonably well controlled, the deceased group had a higher diastolic blood pressure and a wider standard deviation, suggesting more participants were above or at a diastolic pressure of 90 mmHg. Finally, differences in mortality rates when comparing FinnDiane participants to matched controls appeared to be larger for women than men, at least on the relative scale. This is consistent with prior observations that the reduced rates of CVD and death in women versus men that are observed in the general population are blunted in the setting of type 1 diabetes (13).

Group et al. (9) did not find a significant association of baseline hemoglobin A1c with mortality within the FinnDiane subpopulation without DKD. This should not be interpreted to mean that hyperglycemia plays no role in CVD and premature death in type 1 diabetes. First, use of a single baseline value of hemoglobin A1c does not adequately capture cumulative exposure to hyperglycemia. Second, and more importantly, hyperglycemia appears to contribute to CVD and premature death at least in part through the development of microvascular complications, particularly DKD (14). By intentionally excluding FinnDiane participants who developed DKD, the adverse impact of hyperglycemia may be largely outside the scope of the studied subpopulation.

The Diabetes Control and Complications Trial (DCCT) clearly demonstrated that early intensive diabetes therapy substantially reduces the risks of DKD, CVD, and mortality in type 1 diabetes (15–17). In mediation analyses, the effects of intensive diabetes therapy on CVD were completely explained by effects on hemoglobin A1c or partially explained by effects on urine albumin excretion. These results make it clear that hyperglycemia is a primary driver of long-term CVD in type 1 diabetes and suggest that kidney disease is either a mechanism or a marker of this process.

In short, it is known that poor early glycemic control promotes development of DKD, which is associated with increased risk of CVD. Groop et al. demonstrate that acute diabetes complications drive excess mortality early in type 1 diabetes and CVD drives excess mortality later in the disease course. Taken together, these observations reinforce the need to control glycaemia and other CV risk factors early in type 1 diabetes to help prevent DKD and ultimately reduce CVD risk.

Funding and Duality of Interest. I.H.d.B. has received grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, American Diabetes Association, and JDRF and equipment and supplies for research from Medtronic and Abbott (all through his institution) and has consulted within the last couple of years for Boehringer Ingelheim and Ironwood Pharmaceuticals. G.L.B. is a principal investigator for the outcome trial FIDELIO (Bayer), serves on the Steering Committee of the Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE) (Janssen), CALM-2 (Vascular Dynamics), and Study Of Diabetic Nephropathy with Atrasentan (SONAR) (AbbVie), and has also consulted for Merck and Relypsa. No other potential conflicts of interest relevant to this article were reported.

References
1. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364:829–841.
2. Dahlquist G, Källén B. Mortality in childhood-onset type 1 diabetes: a population-based study. Diabetes Care 2005;28:2384–2387.
3. Patterson CC, Dahlquist G, Harjutsalo V, et al. Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989. Diabetologia 2007;50:2439–2442.
4. Tuttle RK, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014;37:2864–2883.
5. Fox CS, Matsushita K, Woodward M, et al.; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012;380:1662–1673.
6. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2010;53:2312–2319.
7. Groop P-H, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009;58:1651–1658.
8. Afkarian M, Sachs MC, Kestenbaum B, et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 2013;24:302–308.
9. Groop P-H, Thomas M, Feooroff M, Forsblom C, Harjutsalo V; FinnDiane Study Group. Excess mortality in patients with type 1 diabetes without albuminuria—separating the contribution of early and late risks. Diabetes Care 2018;41:748–754.
10. Thorn LM, Forsblom C, Fagerudd J, et al.; FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005;28:2019–2024.
11. Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889–2934.
12. Perk J, De Backer G, Golikhe H, et al.; European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635–1701.
13. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care 2016;39:1378–1383.
14. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653.
15. de Boer IH, Sun W, Cleary PA, et al.; DCCT/EDIC Research Group. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011;365:2366–2376.
16. Orchard TJ, Nathan DM, Zinman B, et al.; Writing Group for the DCCT/EDIC Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45–53.
17. de Boer IH, DCCT/EDIC Research Group. Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 2014;37:24–30.